{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:49:09Z","timestamp":1791355749473,"version":"4.3.1"},"reference-count":77,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T00:00:00Z","timestamp":1488240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Influenza Resp Viruses"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:p>Influenza antiviral drugs are important for the control of influenza, most specifically for the treatment of influenza patients with severe disease following infection with a seasonal influenza virus, a newly emerging influenza strain, or in the event of a pandemic. Many influenza antivirals that are currently under investigation in late\u2010stage clinical trials differ in their mechanism of action compared to drugs currently licensed for the treatment of influenza. Nitazoxanide and <jats:styled-content style=\"fixed-case\">DAS<\/jats:styled-content>181 target components of the host cell and alter the ability of the virus to replicate efficiently, while small molecule drugs such as T705, <jats:styled-content style=\"fixed-case\">JNJ<\/jats:styled-content>63623872 and S\u2010033188 bind to the viral polymerase complex and restrict viral replication. Monoclonal antibodies that are currently in clinical trial for the treatment of influenza most commonly are targeted to the stem region of the haemagglutinin molecule. Early findings from animal models and in vitro studies suggest that many of the new antiviral drugs when tested in combination with oseltamivir have improved effectiveness over monotherapy. Clinical trials assessing both monotherapy and combination therapy are currently under investigation. It is hoped that as new antivirals are licensed, they will improve the standard of care and outcomes for influenza patients with severe disease.<\/jats:p>","DOI":"10.1111\/irv.12446","type":"journal-article","created":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T14:36:54Z","timestamp":1485959814000},"page":"240-246","source":"Crossref","is-referenced-by-count":128,"title":["Influenza antivirals currently in late\u2010phase clinical trial"],"prefix":"10.1111","volume":"11","author":[{"given":"Paulina","family":"Koszalka","sequence":"first","affiliation":[{"name":"WHO Collaborating Centre for Reference and Research on Influenza VIDRL Peter Doherty Institute for Infection and Immunity  Melbourne Victoria Australia"},{"name":"University of Melbourne Melbourne School of Population and Global Health  Parkville Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Tilmanis","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Reference and Research on Influenza VIDRL Peter Doherty Institute for Infection and Immunity  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1826-4314","authenticated-orcid":false,"given":"Aeron C.","family":"Hurt","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Reference and Research on Influenza VIDRL Peter Doherty Institute for Infection and Immunity  Melbourne Victoria Australia"},{"name":"University of Melbourne Melbourne School of Population and Global Health  Parkville Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,28]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"10","article-title":"Early estimates of seasonal influenza vaccine effectiveness\u2014United States, January 2015","volume":"64","author":"Flannery B","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.10.002"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep15279"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta20420"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2016.09.024"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki018"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2014.11.020"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-011-0288-0"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1985.tb04038.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67338-2"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.06.001"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.03.003"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1504.181280"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1111078"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES2014.19.1.20666"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP38387"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2.1.43"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01159-06"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.07.014"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2007.08.005"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.7.4027"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.029470"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2016.09.080"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep27148"},{"key":"e_1_2_7_26_1","unstructured":"BelardoG La FraziaS CenciarelliO et\u00a0al.Nitazoxanide a novel potential anti\u2010influenza drug acting in synergism with neuraminidase inhibitors. in 49th Annual Meeting of the Infectious Diseases Society of America. Boston MA: Infectious Diseases Society of America.2011."},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02556-13"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03947-14"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70717-0"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00078-08"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1470-1479.2006"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp421"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12045"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007788"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00389-09"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040206616665971"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1086\/522609"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu105"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq387"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis622"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.09.008"},{"key":"e_1_2_7_42_1","first-page":"1","article-title":"A phase 1 randomized, double\u2010blind, placebo\u2010controlled, crossover trial of DAS181 (Fludase\u00ae) in adult subjects with well\u2010controlled asthma","volume":"16","author":"Colombo RE","year":"2016","journal-title":"BMC Infect Dis"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.09.015"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02346-12"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-001-0308-0"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2012.07.034"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.01.012"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.02.014"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01739-09"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.977-981.2002"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01051-06"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0909603107"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep26742"},{"key":"e_1_2_7_54_1","unstructured":"LTD T.C.C.The New Drug Application Approval of \u201cAVIGAN\u00aeTablet 200\u00a0mg\u201d in Japan for the anti\u2010influenza virus drug 2014."},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1017\/dmp.2014.151"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.06.007"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(81)90449-9"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04623-14"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.07.008"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.10.009"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm5007275"},{"key":"e_1_2_7_62_1","unstructured":"VRTX\u2010GEN.VX\u2010787 Showed Significant Antiviral Activity and Reduced the Severity and Duration of Influenza Symptoms in Phase 2 Challenge Study. 2013 March 2016]."},{"key":"e_1_2_7_63_1","unstructured":"TakekiUehara TS ToruI KeikoK et\u00a0al.S\u2010033188 a Small Molecule Inhibitor of Cap\u2010dependent Endonuclease of Influenza A and B Virus Leads to Rapid and Profound Viral Load Reduction in Options for the Control of Influenza. 28th August 2016.: Chicago USA."},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1205669"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003942"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009106"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1204839"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2014.04.009"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.05.073"},{"key":"e_1_2_7_70_1","unstructured":"AliO.A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Healthy Adults. in IDWeek 2016.2016. Idsa."},{"key":"e_1_2_7_71_1","doi-asserted-by":"crossref","unstructured":"GuptaP KamathAV ParkS et\u00a0al.Preclinical pharmacokinetics of MHAA4549A a human monoclonal antibody to influenza A virus and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A. in mAbs.2016. Taylor & Francis.","DOI":"10.1080\/19420862.2016.1167294"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12293"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00607-16"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.01.012"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02457-15"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.02.021"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0911806107"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu539"}],"container-title":["Influenza and Other Respiratory Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Firv.12446","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/irv.12446","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T05:04:15Z","timestamp":1696482255000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/irv.12446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,28]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1111\/irv.12446"],"URL":"https:\/\/doi.org\/10.1111\/irv.12446","archive":["Portico"],"relation":{},"ISSN":["1750-2640","1750-2659"],"issn-type":[{"value":"1750-2640","type":"print"},{"value":"1750-2659","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,28]]}}}